Anatara Lifesciences
- Short interest
- 0.00%
- −0.01 pp 30d
- as of 14 Oct 2024
- Reported shorts
- 558
- Shares on issue
- 192.894M
Anatara Lifesciences (ANR) financials
Results, ratios and statements
Latest result
Year to 30 Jun 2026 (FY26) vs FY25, figures in AUD, the reporting currency
- Revenue
- $0M (source: ASX (Markit))vs $0M (source: ASX (Markit)) (FY25)
- ASX (Markit), as at 14 Oct 2026
- NPAT
- −$933.2KM (source: ASX (Markit))vs −$2.0MM (source: ASX (Markit)) (FY25)
- ASX (Markit), as at 14 Oct 2026
- EPS (diluted)
- −$0.003T (source: Derived: trailing 12 months at year end)vs −$0.009 (FY25)
- Derived: trailing 12 months at year end, as at 14 Oct 2026
- Rev YoY
- n/aFY
- EPS YoY
- n/aTTM
- ASX (Markit)
- Derived: trailing 12 months at year end
Summary of Appendix 4E & Financial Report 30 June 2026, 18 Aug 2026
Anatara Lifesciences reported a net loss of $933,230 for the year ended 30 June 2026, a 52% improvement (reduction in loss) from the prior year. No dividends were paid or declared. The company is advancing its Anti-Obesity Project and evaluating strategic opportunities, but has placed the project on hold pending further transactions.
Automated summary of the filing; the filing itself is the record.
Key ratios
Year to 30 Jun 2026 (FY); no balance sheet aligned with this period; prices to 14 Oct 2026
- Gross margin
- n/a
- Operating margin
- n/a
- Net margin
- n/a
- FCF margin
- n/a
- ROE
- n/a
- ROA
- n/a
- FCF conversion
- n/a
- Net debt (excl. leases)
- n/a
- Net debt / EBITDA
- n/a
- Current ratio
- n/a
- Interest cover
- −408.7×
- Cash dividends paid / net profit
- n/a
- Market cap
- n/a (no share count we can vouch for)
- P/E
- n/a
- P/B
- n/a (no share count we can vouch for)
Ratios use the reporting currency (AUD); market cap is in AUD. Sources: ASX (Markit) and Derived: trailing 12 months at year end, as at 14 Oct 2026.
Financial statements
Figures in AUD, the reporting currency; Yahoo Finance unless marked
| Line item | FY26 | FY25 | FY24 | FY23 |
|---|---|---|---|---|
| Revenue | $0M (source: ASX (Markit)) | $0M (source: ASX (Markit)) | $0M (source: ASX (Markit)) | $0M (source: ASX (Markit)) |
| Operating income | −$1.3MT (source: Derived: trailing 12 months at year end) | n/a | −$2.1M | −$3.3M |
| EBITDA | −$930.1KT (source: Derived: trailing 12 months at year end) | n/a | −$2.1M | −$2.0M |
| EBIT | −$930.2KT (source: Derived: trailing 12 months at year end) | n/a | −$2.1M | −$2.0M |
| Interest expense | $3.1KT (source: Derived: trailing 12 months at year end) | n/a | n/a | $2.4K |
| Pretax income | −$933.2KT (source: Derived: trailing 12 months at year end) | n/a | −$1.5M | −$2.0M |
| Tax | $0T (source: Derived: trailing 12 months at year end) | n/a | $0 | $0 |
| NPAT | −$933.2KM (source: ASX (Markit)) | −$2.0MM (source: ASX (Markit)) | −$1.5M | −$2.0M |
| Net interest income | $1.9KT (source: Derived: trailing 12 months at year end) | n/a | $7.9K | $15.9K |
| EPS basic | −$0.003T (source: Derived: trailing 12 months at year end) | −$0.009 | −$0.010 | −$0.019 |
| EPS diluted | −$0.003T (source: Derived: trailing 12 months at year end) | −$0.009 | −$0.010 | −$0.019 |
| Shares | n/a | n/a | 191.1M | 127.7M |
- ASX (Markit)
- Derived: trailing 12 months at year end
Financial reports
The company's own filings, newest first
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report13 Oct 2026via asx_announcements
- Appendix 4E & Financial Report 30 June 2026Annual Results18 Aug 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report31 Jul 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report29 Apr 2026via asx_announcements
- Appendix 4D & Half Year Report 31 December 2025Half Year Results25 Feb 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report30 Jan 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report23 Oct 2025via asx_announcements
- Annual Report to shareholdersAnnual Report17 Oct 2025via asx_announcements
- Appendix 4E & Financial Report 30 June 2025Annual Results13 Aug 2025via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report29 Jul 2025via asx_announcements
Showing 10 of 30 reports